(Q44131798)

30 November 2017

title

Fluticasone is associated with lower asthma-related costs than leukotriene modifiers in a real-world analysis (English)

1 reference

30 November 2017

1 reference

Edward P Armstrong

1

1 reference

30 November 2017

Daniel C Malone

series ordinal

2

1 reference

30 November 2017

language of work or name

English

0 references

publication date

1 September 2002

1 reference

30 November 2017

1 reference

30 November 2017

volume

22

1 reference

30 November 2017

issue

9

1 reference

30 November 2017

page(s)

1117-1123

1 reference

Health care utilization and cost among children with asthma who were enrolled in a health maintenance organization

30 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.13.1117.33515

Comprehensive asthma management: guidelines for clinicians

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.13.1117.33515

Corticosteroids and leukotrienes: chronobiology and chronotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.13.1117.33515

Low-dose fluticasone propionate compared with montelukast for first-line treatment of persistent asthma: a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.13.1117.33515

A chronic disease score from automated pharmacy data

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.13.1117.33515

Economic impact of asthma therapy with fluticasone propionate, montelukast, or zafirlukast in a managed care population

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.13.1117.33515

Fluticasone alone or in combination with salmeterol vs triamcinolone in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.13.1117.33515

Inhaled fluticasone propionate. A pharmacoeconomic review of its use in the management of asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.13.1117.33515

Cost implications for the use of inhaled anti-inflammatory medications in the treatment of asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.13.1117.33515

One-year claims analysis comparing inhaled fluticasone propionate with zafirlukast for the treatment of asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.13.1117.33515

Comparison of asthma costs in patients starting fluticasone propionate compared to patients starting montelukast

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.13.1117.33515

A comparison of asthma-related expenditures for patients started on montelukast versus fluticasone propionate as monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.13.1117.33515

Adherence to oral montelukast and inhaled fluticasone in children with persistent asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.13.1117.33515

10.1592/PHCO.22.13.1117.33515

21 January 2018

Identifiers

DOI

1 reference

30 November 2017

1 reference